Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Roger Jeffs
AddedMar 31, 2024
UpdatedJun 28, 2026
Roger Jeffs

Roger Jeffs

Board Member, Axsome Therapeutics

Crunchbase

Roger Jeffs's Career

Axsome Therapeutics
Axsome Therapeutics

New York City, NY, US

Board Member· Board
Spyryx Biosciences
Spyryx Biosciences

Durham, NC, US

Board Member· Board
Kriya Therapeutics
Kriya Therapeutics

Palo Alto, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Roger Jeffs's Career

Axsome Therapeutics
Axsome Therapeutics
Public$432M3832012New York City, NY, US
Board Member· Board

Leadership at Axsome Therapeutics

Mark SaadMark SaadBoard Member
Herriot TabuteauHerriot TabuteauBoard Member
Spyryx Biosciences
Spyryx Biosciences
Series A$18.2M302013Durham, NC, US
Board Member· Board

Leadership at Spyryx Biosciences

Brian DanielsBrian DanielsBoard Member
Christy ShafferChristy ShafferBoard Member
Robert TarranRobert TarranFounder
Tim ShannonTim ShannonBoard Member
John C TaylorJohn C TaylorCEO

Similar to Spyryx Biosciences

SynspiraSynspiraFramingham, MA, USBiotechest. 2017SynspiraFramingham, MA, US · est. 2017

Synspira Therapeutics: A clinical-stage biotech firm innovating treatments for cystic fibrosis and rare diseases.

Series B · $25.2M8
PulmatrixPulmatrixLexington, MA, USTherapeuticsest. 2003PulmatrixLexington, MA, US · est. 2003

Pulmatrix, Inc.: A US-based biotech firm specializing in therapies for chronic respiratory diseases.

Public · $148.4M24
Spirrow TherapeuticsSpirrow TherapeuticsBoston, MA, USLung Restorationest. 2018Spirrow TherapeuticsBoston, MA, US · est. 2018

Spirrow Therapeutics: Innovating lung restoration for ARDS-affected babies using proprietary methods.

Angel · $256k6
Kriya Therapeutics
Kriya Therapeutics
Series C$600.5M1942019Palo Alto, CA, US
Board Member· Board

Leadership at Kriya Therapeutics

Jim MomtazeeJim MomtazeeBoard Member
Shankar RamaswamyShankar RamaswamyCo-Founder
Fraser WrightFraser WrightCo-Founder

Similar to Kriya Therapeutics

Voyager TherapeuticsVoyager TherapeuticsCambridge, MA, USGene Therapyest. 2014Voyager TherapeuticsCambridge, MA, US · est. 2014

Cambridge-based Voyager Therapeutics, Inc. is a clinical-stage gene therapy company developing treatments for severe CNS diseases.

Public · $374M125
NephrogenNephrogenNew York City, NY, USGene Therapiesest. 2020NephrogenNew York City, NY, US · est. 2020

Nephrogen: Crafting gene cures for kidney diseases, focusing on PKD.

Seed · $150k1
Kate TherapeuticsKate TherapeuticsSan Diego, CA, USGene TherapyKate TherapeuticsSan Diego, CA, US

KateTx, a gene therapy biotech firm, focuses on developing AAV-based therapies for genetic muscle and heart diseases.

Series A · $51M44

Roger Jeffs's Co-Investors

Paul ManningPaul ManningCo-invested · Liquidia Post Ipo EquityAMDG 1AMDG 1Co-invested · Liquidia Post Ipo EquityJenny RookeJenny RookeCo-invested · Liquidia Series UnknownWilliam N. StarlingWilliam N. StarlingCo-invested · Liquidia Series ALowry CaudillLowry CaudillCo-invested · Liquidia Series AAlfred ChildersAlfred ChildersCo-invested · Liquidia Series A

Roger Jeffs's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Roger Jeffs

Jacob ShidlerJacob ShidlerCo-Founder · LiquidRobin ObermaierRobin ObermaierCEO · liquidiumSteve NelsonSteve NelsonBoard Member · Blue CrossDerek HopkinsDerek HopkinsCEO · Liquid Health LabsSaujin YiSaujin YiFounder · LiquidJim ToffeyJim ToffeyCEO · LiquidX